A COVID-19 treatment drug candidate from S. Korean firm Celltrion will be given to high-risk patients this month even before being granted approval as part of a separate clinical trial.
The Central Disaster Management Headquarters says the clinical trial will help determine whether the drug is effective against the new COVID-19 variant currently sweeping the UK and South Africa.
Meanwhile, South Korea’s food and drug safety ministry will begin the first stage of a three-part review process on Sunday to ensure the drug’s safety and efficacy.

Reporter :


Source Link

This page is made available thanks to China Press Release by Topic News

Leave a Reply

Your email address will not be published.